mTORC1 serves as a downstream effector for several commonly disrupted oncogenic pathways, including the PI3K/AKT and MAPK pathways, and the mTOR pathway is overactive in various tumor types, making mTOR a target for cancer treatment. This evidence concerns the gene PIK3CG and neoplasm.